Suppr超能文献

瑞典队列中丛集性头痛的处方治疗与非处方治疗的使用情况

Use of Prescribed and Non-Prescribed Treatments for Cluster Headache in a Swedish Cohort.

作者信息

Smedfors Gabriella, Jennysdotter Olofsgård Felicia, Steinberg Anna, Waldenlind Elisabet, Ran Caroline, Belin Andrea Carmine

机构信息

Centre for Cluster Headache, Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden.

Department of Clinical Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden.

出版信息

Brain Sci. 2024 Mar 31;14(4):348. doi: 10.3390/brainsci14040348.

Abstract

BACKGROUND

Cluster headache (CH) is a debilitating condition, but current therapies leave CH patients in pain. The extent of this problem in Sweden is unknown.

METHODS

An anonymized questionnaire was sent to 479 Swedish CH patients to investigate patterns and perceived effects of treatments.

RESULTS

Three hundred fourteen answers were analyzed. The population was representative regarding age of onset and sex. Less than half (46%) were satisfied with their abortive treatments, 19% terminated functioning abortive treatments due to side effects. Additionally, 17% of chronic CH patients had not tried the first-line preventive drug verapamil. A small subset had tried illicit substances to treat their CH (0-8% depending on substance). Notably, psilocybin was reported effective as an abortive treatment by 100% ( = 8), and with some level of effect as a preventive treatment by 92% ( = 12). For verapamil, some level of preventive effect was reported among 68% ( = 85).

CONCLUSIONS

Our descriptive data illustrate that many Swedish CH patients are undertreated, lack functional therapies, and experience side effects. Further studies are warranted to search for new treatment strategies as well as a revision of current treatment guidelines with the aim of reducing patient disease burden to the greatest extent possible.

摘要

背景

丛集性头痛(CH)是一种使人衰弱的疾病,但目前的治疗方法仍使CH患者饱受疼痛折磨。瑞典这一问题的严重程度尚不清楚。

方法

向479名瑞典CH患者发送了一份匿名问卷,以调查治疗模式和感知到的治疗效果。

结果

分析了314份回复。该人群在发病年龄和性别方面具有代表性。不到一半(46%)的患者对其发作期治疗感到满意,19%的患者因副作用而停止使用有效的发作期治疗药物。此外,17%的慢性CH患者尚未尝试一线预防性药物维拉帕米。一小部分患者曾尝试使用非法药物治疗CH(根据药物不同,比例为0 - 8%)。值得注意的是,100%(n = 8)的患者报告裸盖菇素作为发作期治疗有效,92%(n = 12)的患者报告其作为预防性治疗有一定程度的效果。对于维拉帕米,68%(n = 85)的患者报告有一定程度的预防效果。

结论

我们的描述性数据表明,许多瑞典CH患者治疗不足,缺乏有效的治疗方法,且经历副作用。有必要进行进一步研究以寻找新的治疗策略,并修订当前的治疗指南,以尽可能减轻患者的疾病负担。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13f5/11048603/328f65e9cfff/brainsci-14-00348-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验